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Background: Stroke prevention bywarfarin, a vitamin K antagonist, has been an integral part in themanagement
of atrial ﬁbrillation. Vitamin K-dependent matrix Gla protein (MGP) has been known as a potent inhibitor of
arterial calciﬁcation and osteoporosis. Therefore, we hypothesized that warfarin therapy affects bone mineral
metabolism, vascular calciﬁcation, and vascular endothelial dysfunction.
Methods:We studied 42 atrial ﬁbrillation patients at high-risk for atherosclerosis having one or more coronary
risk factors. Twenty-four patients had been treated with warfarin for at least 12 months (WF group), and 18 pa-
tients without warfarin (non-WF group). Bone alkaline phosphatase (BAP) and under carboxylated osteocalcin
(ucOC) and receptor activator of nuclear factor-kappa B ligand (RANKL) were measured as bone metabolism
markers. Reactive hyperemia-peripheral arterial tonometry (RH-PAT) index measured by Endo-PAT2000 was
used as an indicator of vascular endothelial function.
Results: There were no signiﬁcant differences in patient background characteristics and other clinical indicators
between the two groups. In WF group, the ucOC levels were signiﬁcantly higher than those in the non-WF
group (10.3 ± 0.8 vs. 3.4 ± 0.9 ng/mL; P b 0.01), similarly, the RANKL levels in the WF group were higher than
those in the non-WF group (0.60 ± 0.06 vs. 0.37± 0.05 ng/mL; P=0.007). Moreover, RH-PAT index was signif-
icantly lower in theWF group compared to those in the non-WF group (1.48 ± 0.11 vs. 1.88± 0.12; P=0.017).
Conclusions: Long-term warfarin therapy may be associated with bone mineral loss and vascular calciﬁcation in
60–80 year old hypertensive patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Until recently, warfarin and other vitamin K antagonists have been
the only class of oral anticoagulants available for atrial ﬁbrillation to
reduce the risk of stroke. However, their use has been limited by a
narrow therapeutic range that necessitates frequent monitoring and
dose adjustments resulting in substantial risk and inconvenience [1].
There are three typical Vitamin K dependent proteins: osteocalcin
(OC), matrix Gla protein (MGP), and growth arrest speciﬁc protein 6
(Gas-6) which play key functions in maintaining bone strength, vascu-
lar calciﬁcation inhibition, and cell growth regulation, respectively. Onaline phosphatase; ucOC, under
clear factor-kappa B ligand; RH-
OC, osteocalcin; Gas-6, growth
ity; DXA, dual-energy X-ray
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. This is an open access article underthe other hand, warfarin prevents the activation of MGP and Gas-6;
therefore, long-term use of warfarin is reported to be associated with
osteoporotic fractures [2]. In addition, it is known that low vitamin K
is associated with reduced bone mineral density (BMD) [3]. BMD tests
can identify osteoporosis and determine the risk for fractures [4].
According to previous studies of ectopic calciﬁcation in osteoporosis
patients and their animal models, we hypothesized that long-term
warfarin therapy affects both bone mineral metabolism and vascular
calciﬁcation [5,6]. We examined blood biomarkers relating to BMD
and vascular endothelial function in atrial ﬁbrillation patients with or
without long-term warfarin therapy.
2. Materials and methods
2.1. Subjects
Patients were recruited from June 2013 to February 2014 at the
Kitasato University Hospital and Kitasato University East Hospital,
who were treated for atrial ﬁbrillation at high-risk for atherosclerosisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients' characteristics at baseline.
Patients' characteristics
WF group
(n = 24)
Non-WF group
(n = 18)
P value
Demographic data
Age (years) 68.6 ± 1.4 67.1 ± 1.5 0.47
Males, n (%) 22 (92) 14 (78) 0.25
Risk factors
Hypertension, n (%) 18 (75) 11 (61) 0.15
Dyslipidemia, n (%) 8 (33) 2 (11) 0.07
Diabetes, n (%) 5 (21) 2 (11) 0.68
Smoking, n (%) 16 (67) 11 (61) 0.59
BMI (kg/m2) 24.1 ± 0.6 22.4 ± 0.7 0.06
CHADS2 score 1.4 ± 0.1 0.8 ± 0.2 0.02
The CHADS2 score is a clinical prediction score for estimating the risk of stroke in patients
with non-rheumatic atrial ﬁbrillation. Values are means ± SD.
WF: warfarin; BMI: body mass index.
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patients with hypertension were entered into the study. The exclusion
criteriawere as follows: CHADS2 scores N4, age N 80 years old, hemoglo-
bin A1c (HbA1c) N 8.0% and blood pressure (BP) N 160/100 mm Hg. All
subjects were given informed consent before participating in the study.
The study was approved by the Scientiﬁc and Ethical Committee of the
Kitasato University School of Medicine, Sagamihara, Japan.
2.2. Blood sample collection and measurement of clinical biomarkers
Blood samples were collected from all participants by venipuncture
after an overnight fast. Biochemical markers, such as triglyceride, low-
density lipoprotein cholesterol (LDL-C), high density lipoprotein choles-
terol (HDL-C), plasma glucose, HbA1c, uric acid (UA), gamma-glutamyl
transpeptidase (γ-GTP), C-reactive protein (CRP), and brain natriuretic
peptide (BNP) were measured. BAP and ucOC were measured as bone
metabolism markers.
2.3. Measurement of cytokines
Blood samples for cytokine measurements were centrifuged for
10min at approximately 3000 r/min 4 °C, and the serumwas separated
and stored at−80 °C prior to analysis. We measured seven circulating
serum cytokine levels. Circulating levels of receptor activator of nuclear
factor-kappa B ligand (RANKL), adiponectin, monocyte chemotactic
protein-1 (MCP-1), interleukin-6 (IL-6), human pentraxin 3 (PTX3),
interleukin-18 (IL-18), and tumor necrosis factor-α (TNF-α) were de-
termined by enzyme-linked immunosorbent assay (ELISA) according
to themanufacturer's instructions. ELISA Kit for receptor activator of nu-
clear factor kappa B ligand (USCN Life Science Inc., Houston, TX), human
total adiponectin/Acrp30 Quantikine ELISA Kit, human CCL2/MCP-1
Quantikine ELISA Kit, human interleukin-6 (IL-6) Quantikine ELISA Kit,
human pentraxin 3/TSG-14 Quantikine ELISA Kit, human TNF-α
Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis, MN), and
human IL-18 ELISA Kit (MBL International, Woburn, MA) were used.
2.4. Measurement of vascular endothelial function by Endo-PAT2000
Vascular endothelial function was examined by reactive hyperemia
using Endo-PAT2000 (ItamarMedical Ltd., Caesarea, Israel). Using a ﬁn-
gertip peripheral arterial tonometry device, we measured digital pulse
amplitude in the supine position to patients for 5 min at baseline and
after a reactive hyperemia induced by a 5-min forearm cuff occlusion
[7]. RH-PAT was measured in fasting condition. Before measurement,
patientswere asked to rest for 10min. The datawere digitized and com-
puted automatically with Endo-PAT2000 software; the digital reactive
hyperemia peripheral arterial tonometry (RH-PAT) index, representing
the endothelial function, was deﬁned as the ratio of the mean post-
deﬂation signal (in the 90 to 120-s post-deﬂation interval) to the
baseline signal in the hyperemic ﬁnger and was normalized by the
same ratio in the contra-lateral ﬁnger and was multiplied by a baseline
correction factor, as calculated by the Endo-PAT2000 software.
2.5. Peripheral atherosclerosis assessment
Aortic stiffness was assessed by pulse wave velocity (PWV) and the
average of the left and right values was used in the analysis. Ankle-
brachial index (ABI) was calculated by dividing the highest systolic
blood pressure in each ankle by the highest brachial pressure, and the
average of the left and right values was also used in the analysis.
2.6. Assessment of bone mineral density
Dual-energy X-ray absorptiometry (DXA) measurements were used
to detect bone mineral density. The DXA was used to measure femurneck and lumbar spine (Hologic Inc., Bedford, MA). Standardized data
acquisition and analysis techniques were used.
2.7. Statistical analysis
Continuous data are summarized as either mean ± SD or median,
and categorical data are expressed as percentages. Data were compared
by unpaired t-test or theMann–Whitney U-test where appropriate. Dif-
ferences in proportions of variables were determined by chi-squared
analysis. To evaluate the correlations between endothelial function
and selected variables, we calculated the Spearman correlation
coefﬁcients between RH-PAT index and the following variables: 1) con-
ventional risk factors for cardiovascular disease: LDL-C, HDL-C, triglyc-
eride, HbA1c, presence of hypertension, body mass index (BMI), and
previous smoking, and history of coronary artery disease; 2) osteoporo-
sis and vascular calciﬁcation-relatedmarkers (ucOC, RANKL, DXA, PWV,
ABI). All parameterswith statistical signiﬁcance (P b 0.05) in the univar-
iate analysiswere entered into themultivariate Cox-regression analysis.
We conductedmultivariate logistic regressionmodels to assesswhether
circulating RANKL was independently associated with RH-PAT index.
3. Results
3.1. Subject characteristics
We recruited 42 atrial ﬁbrillation patients having one or more coro-
nary risk factors in the clinic of Cardiovascular Medicine, Kitasato Uni-
versity Hospital and Kitasato University East Hospital (average age
68 years old, 15% female). Twenty-four patients who had been treated
with warfarin at least 12 months were enrolled as the warfarin group
(WF group), and 18 patients treated without warfarin were also
enrolled as the non-warfarin group (non-WF group). Among the 18 pa-
tients, 10 patients received dabigatran, and 1 patient received apixaban.
3.2. Long-term warfarin therapy and atherosclerosis
As shown in Table 1, there were no signiﬁcant differences in patient
background characteristics between the WF group and the non-WF
group, including coronary risk factors. As shown in Table 2, there was
no signiﬁcant difference in PWV. In addition, circulating levels of CRP
and ABI were not different between the two groups.
3.3. Calciﬁcation related biomarkers
There were signiﬁcant differences in circulating levels of ucOC and
RANKL between the two groups (Table 2). Serum levels of ucOC were
signiﬁcantly higher in the WF group than those in the non-WF group
(10.3 ± 0.8 vs. 3.4 ± 0.9 ng/mL; P b 0.01) (Fig. 1A). Serum levels of
RANKL in the WF group were higher than those in the other (0.6 ±
Table 2
Patients' clinical data.
Patients' clinical data
WF group
(n = 24)
Non-WF group
(n = 18)
P value
Labo data
P (mg/dL) 3.1 ± 0.1 3.5 ± 0.2 0.09
Ca (mg/dL) 9.2 ± 0.1 9.1 ± 0.1 0.35
BAP (U/L) 12.6 ± 1.0 11.4 ± 1.1 0.39
ucOC (ng/mL) 10.3 ± 0.8 3.4 ± 0.9 b0.01⁎
Physiological function test
RH-PAT index 1.5 ± 0.1 1.9 ± 0.2 0.02⁎
PWV (m/s) 1672 ± 65 1536 ± 74 0.18
Bone mineral density
DXA (g/cm2) 1.1 ± 0.1 1.0 ± 0.1 0.19
Cytokines
RANKL (ng/mL) 0.6 ± 0.1 0.4 ± 0.1 b0.01⁎
Adiponectin (ng/mL) 7.6 ± 0.1 8.6 ± 1.2 0.56
MCP-1 (pg/mL) 192.3 ± 39.9 102.4 ± 41.0 0.13
IL-6 (pg/mL) 1.6 ± 0.3 0.8 ± 0.3 0.13
Pentraxin3 (ng/mL) 2.1 ± 0.3 2.2 ± 0.3 0.82
IL-18 (pg/mL) 309.2 ± 19.4 256.6 ± 19.9 0.07
TNF-α (pg/mL) 0.54 ± 0.03 0.51 ± 0.03 0.60
Values are means ± SD. WF: warfarin; BAP: bone alkaline phosphatase; ucOC: under car-
boxylated osteocalcin; RH-PAT index: reactive hyperemia-peripheral arterial tonometry
index; PWV: pulse wave velocity; DXA: Dual-energy X-ray absorptiometry; RANKL:
receptor activator of nuclear factor-kappaB ligand; MCP-1: monocyte chemotactic
protein-1; IL-6: interleukin-6; IL-18: interleukin-18 and TNF-α: tumor necrosis factor-α.
⁎ P b 0.05.
78 S. Namba et al. / BBA Clinical 4 (2015) 76–800.1 vs. 0.4± 0.1 ng/mL; P b 0.01) (Fig. 1B). On the other hand, therewas
no signiﬁcant difference in DXA (P=0.19) or prior history of bone frac-
ture between the two groups.
3.4. Vascular endothelial function
RH-PAT is a noninvasive technique to assess the peripheral micro-
vascular endothelial function by measuring changes in the digitalFig. 1. A. A bone metabolism marker, serum levels of ucOC, were signiﬁcantly higher in warfa
vascular inﬂammatorymarker, serum levels of RANKL, were higher in thewarfarin group than t
with atrial ﬁbrillation. Reactive hyperemia-peripheral arterial tonometry (RH-PAT) index wa
means ± SD. * P b 0.05. ucOC: under carboxylated osteocalcin; BAP: bone alkaline phosphataspulse volume during reactive hyperemia. RH-PAT index in WF group
was signiﬁcantly lower compared to those in the non-WF group
(1.5 ± 0.1 vs. 1.9 ± 0.16; P = 0.02) (Fig. 1C). Several clinical factors
were associated with the RH-PAT index on univariate analysis
(Table 3): BMI, HbA1c, BNP, LDL-C. However, serum levels of ucOC
and RANKL were not correlated with RH-PAT index. The multivariate
analysis revealed that BMI and BNP were independent predictors of
endothelial dysfunctionmeasured by RH-PAT. Those factors were nega-
tively correlated with RH-PAT index (the BMI βwas−0.370with a 95%
CI of−0.116 to−0.007; P=0.027, theBNPβwas−0.306with a 95%CI
of−0.003 to−1.265; P= 0.049).
4. Discussion
The present study demonstrated that long-term warfarin therapy
was associated with: 1) higher ucOC, a vitamin K-dependent bone re-
sorption marker; 2) higher level of RANKL and 3) lower RH-PAT
index. Although it was reported that long-term warfarin therapy was
related to the progression of aortic stiffness in hemodialysis patients,
PWV and DXA were not related in patients with long-term warfarin
therapy [8]. In terms of early prediction of atherosclerosis, this is the
ﬁrst report to evaluate the association of long-term warfarin therapy
with endothelial function.
Since warfarin is a vitamin K antagonist, patients who are on
warfarin therapy must be prohibited from taking vitamin K-rich foods.
Vitamin K-dependent bone proteins and extracellular matrix such as
OC, MGP, and Gas-6 play an important role in controlling bone remod-
eling [3,9]. These proteins and their matrix are activated with γ-
carboxylation of glutamic acid residues. The fraction of imperfect γ-
carboxylation is referred to as ucOC, which is produced and released
from osteoblasts into the vitamin K insufﬁciency or deﬁciency. Serum
ucOC is rapidly decreased with Vitamin K2 treatment [10]. On the
other hand, regular intake of vitamin K increases BMD, and reduces
the bone fracture risk [11]. Therefore, the high level of serum ucOC in-
duced by long-term warfarin therapy is considered one of the risks ofrin therapy patients rather than those in the non-warfarin group. B. Atherosclerosis and
hose in the non-warfarin group. C. Pulse wave velocity and endothelial function in patients
s signiﬁcantly lower in warfarin group compared to that of the other group. Values are
e and RANKL: receptor activator of nuclear factor-kappaB ligand.
Table 3
Univariate and multivariate analysis of clinical factors associated with the RH-PAT index.
Univariate Multivariate
Variable β 95% CI P value β 95% CI P value
Age (years) −0.184 −0.042 to 0.013 0.289
HR (/min) −0.332 −0.029 to 8.284 0.05
BMI (kg/m2) −0.542 −0.143 to−0.042 b0.001⁎ −0.370 −0.116 to−0.008 0.027⁎
CHADS2 score −0.191 −0.372 to 0.108 0.271
HbA1c (%) −0.457 −0.639 to−0.107 0.008⁎ −0.113 −0.362 to 0.184 0.510
LDL-C (mg/dl) 0.364 0.0005 to 0.015 0.037⁎ 0.244 −0.012 to 0.244 0.108
BNP (pg/mL) −0.492 −0.005 to−0.001 0.003⁎ −0.306 −0.004 to−1.265 0.049⁎
eGFR (mL/min) −0.008 −0.012 to 0.012 0.962
P (mg/dL) −0.099 −0.393 to 0.232 0.602
Ca (mg/dL) 0.009 −0.554 to 0.581 0.962
BAP (U/L) 0.132 −0.025 to 0.055 0.449
ucOC (ng/mL) −0.147 −0.049 to 0.020 0.398
PWV (m/s) 0.020 −0.0007 to 0.0007 0.914
RANKL (ng/mL) −0.204 −0.019 to 0.005 0.240
Adiponectin (ng/mL) −0.063 −0.041 to 0.029 0.724
IL-6 (pg/mL) −0.164 −0.172 to 0.063 0.355
TNF-α (pg/mL) −0.050 −0.033 to 0.025 0.779
Values are means ± SD.
HR: heart rate; BMI: body mass index; BAP: bone alkaline phosphatase; ucOC: under carboxylated osteocalcin; RH-PAT index: reactive hyperemia-peripheral arterial tonometry index;
PWV: pulse wave velocity; RANKL: receptor activator of nuclear factor-kappaB ligand; TNF-α: tumor necrosis factor-α.
⁎ P b 0.05.
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value to determine vitaminK insufﬁciency or deﬁciency for osteoporotic
fractures [10]. In addition, it was also reported that serum ucOC is an in-
dependent determinant of carotid artery calciﬁcation and negatively
correlates with renal function [12]. In the present study, we showed
that serum ucOC level was three-times higher in long-term warfarin
therapy patients compared to that in non-warfarin therapy patients.
In the non-WF group, the circulating level of ucOC was within the
normal range. Although the bone mineral density measured by DXA
was not reduced in our study patients, long-term warfarin therapy
may increase the risk of patient's osteoporosis in their future.
In addition, not only serumucOC but also RANKLwas higher in long-
termwarfarin therapypatients than that in the non-WFgroup. RANKL is
a membrane binding type protein and a member of the TNF super fam-
ily. An increasing level of RANKLwas reported in vascular inﬂammation,
atherosclerosis, and osteoporosis [13,14,15]. RANKL is expressed on the
surface of osteoblasts and osteoclast precursor cells, promotes differen-
tiation of osteoclast and induces the activity of bone resorption [16]. In-
timal atherosclerotic calciﬁcation is the most common form of calcium
accumulation, in association with macrophages and vascular smooth
muscle cells (VSMCs). It is seen in peoplewith risk factors of atheroscle-
rosis development, and also in patients suffering from chronic arterial
hypertension or osteoporosis [17]. Recent studies showed that, RANKL
was able to induce VSMC calciﬁcation in vitro by binding to RANK [18,
19]. In this study, serum ucOC and RANKL were higher in the WF
group, which suggests that vascular inﬂammation, calciﬁcation, and
osteoporosis are increased in these patients. Long-term warfarin thera-
py might be associated with the high risk of osteoporosis and ectopic
calciﬁcation in vasculature or heart valves.
Atrial ﬁbrillation is associated with vascular thrombosis and inﬂam-
mation and endothelial dysfunction [20]. We examined endothelial
function using EndoPAT2000, which provides reliable and reproducible
assessments of endothelial function [21,22,23]. RH-PAT index is a repro-
ducible and less operator-dependent technique for endothelial function
assessment that noninvasively reﬂects coronary endothelial function. In
addition, RH-PAT index well reﬂects the risk factors of metabolic syn-
drome including obesity, and high cholesterol, diabetes, smoking [20].
Ohno Y. et al. reported that, an RH-PAT index value of b1.67 is consid-
ered to indicate endothelial dysfunction in a population at risk for ische-
mic heart disease [24]. We showed that the RH-PAT index in the WF
group was signiﬁcantly lower than that in the non-WF group. In addi-
tion, we found that BMI and BNP were independent predictors ofendothelial dysfunction measured by RH-PAT index. However, patients
in the present study were not that of severe obesity or severe heart fail-
ure (the BMI median 23.4, the BNP median 84.2). Previous studies
showed that, atrial ﬁbrillation is associated with impairment of endo-
thelial dysfunction [25]. In addition, patients with obesity, diabetes
mellitus, and dyslipidemia have been associated with impaired vasodi-
lator responses [26,27]. A lower level of digital hyperemia reaction in
obese patients is consistent with impaired microvessel ﬂow reserve,
whichmay contribute to impaired bloodﬂowsupply in the setting of in-
creasedmetabolic demand [28]. Pauriah et al. reported that plasma BNP
was found to be an independent predictor of endothelial function in
several biomarkers assessed by the invasive acetylcholine induced fore-
arm vasodilatation technique [29]. Therefore, we considered that the
atrial ﬁbrillation patients who are obese, or have high levels of BNP
might be at an increased risk of vascular endothelial dysfunction. Endo-
thelial dysfunction is a key component of atherosclerosis and contrib-
utes to the development of clinical cardiovascular diseases [30].
Taking into consideration that the decrease of the RH-PAT index in the
WF group was relatively mild compared to previous studies of patients
with coronary heart disease or high-risk patients of atherosclerosis, fur-
ther studies are needed to examine the correlation between the RH-PAT
index and various coronary risk factors to predict atherosclerosis pro-
gression and prevent cardiovascular diseases.
The WASID (Warfarin–Aspirin Symptomatic Intracranial Disease)
study reported that, they compared the efﬁcacy of warfarin with aspirin
for the prevention of major vascular events (ischemic stroke, myocardi-
al infarction, or sudden death) in patients with symptomatic stenosis of
a major intracranial artery, incidence of major vascular events was sig-
niﬁcantly lower in the warfarin group [31]. Recently, NOAC are rapidly
integrated into clinical practice, warfarin is still an essential anticoagu-
lant for artiﬁcial heart valve replacement surgery and intraventricular
thrombus. Even though long-term warfarin therapy was associated
with decreased vitaminKdependent boneproteins and promotes endo-
thelial dysfunction, warfarin must be one of the important anticoagu-
lant therapeutic strategies in future clinical settings. In the present
study, we found that in osteoporosis patients who require long-term
warfarin therapy, the limit of vitamin K intake is not preferable. There-
fore, we should change to other anticoagulants as possible. In patients
who can't change the warfarin, we conduct the screening of osteoporo-
sis and it seems to be preferable to consider the treatment of osteoporo-
sis other than vitamin K2 as necessary. However, since there is no
evidence such as therapy is effective, further study is needed in the
80 S. Namba et al. / BBA Clinical 4 (2015) 76–80future. In addition, among patients at high-risk of atherosclerosis, pa-
tients who can't change warfarin are also need to be measured the en-
dothelial function on a regular basis. Furthermore, it is important to
control the other factors that cause vascular endothelial dysfunction.
Therefore, it is important that we understand the effects and risks of
warfarin therapy, especially in high-risk patients with osteoporosis
and atherosclerosis.
5. Study limitations
This was an observational single-center prospective study with a
limited number of patients, posing a signiﬁcant risk of selection bias.
We have measured the RH-PAT index to detect endothelial function,
and some patients could not be measured by the RH-PAT index auto-
matically due to tachy-arrhythmias. Because of the technical limitation,
we had to exclude 7 patients from the study.
6. Conclusions
Long-term warfarin therapy may be associated with bone mineral
loss and vascular calciﬁcation in 60–80 year old hypertensive patients.
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